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SACRAL NEUROMODULATION IN THE MANAGEMENT OF LOWER URINARY TRACT 
DYSFUNCTIONS: A NEUROPHYSIOLOGICAL EVALUATION  
 
Hypothesis / aims of study 
Currently, sacral neuromodulation (SNM) stands as the single licensed second-line treatment for the management of intractable 
overactive bladder syndrome (OAB). SNM can be considered a promising, potential solution to bladder dysfunctions which have 
a serious impact on patients’ health status and quality of life, in carefully selected patients. However several questions are still 
unanswered, regarding the following topic: patient selection, prognostic factors, mechanism of action, complications and 
revision rates, effects on central and peripheral nervous system. Neurophysiology studies could be employed to provide more 
evidence on SNM mechanism of action and peripheral effect. The aim of this study was to evaluate clinical and 
neurophysiologic characteristics of patients with lower urinary tract dysfunctions (LUTD) undergone SNM implant trying to better 
understand neurophysiologic modification pre- and post-implant, defining responders’ pre-implant neurophysiological 
characteristics.  
 
Study design, materials and methods 
Data (demographics, medical history,urologic investigations, and diagnosis) from all patients attending our institution from 
February 2006 to September 2009 for a SNM implant were collected. All patients underwent a pre-implant neurophysiologic 
evaluation as follows: Pudendal Nerve Somatosensory Evoked Potentials (PN-SSEPs); bilateral external anal sphincter 
electromyography (EAS-EMG); evaluation of the bilateral pudendal-anal reflex (PAR); Electromyographic and neurographic 
studies of lower limbs. A post-implant neurophysiological evaluation was performed in all implant removal candidates. For 
comparison Student's t test was used.  
 
Results 
A total of 22 consecutive patients (mean age 63.1 years) attending our institution (19 women and 3 men), with refractory 
overactive bladder (OAB) (54.5%), non-obstructive urinary retention (UR) (27.3%), mixed urinary incontinence (9.1%); chronic 
pelvic pain (CPP) (9.1%) underwent a permanent SNM implant. At a mean follow-up of 3.5 months (range 2-24 months), half of 
the patients have their implants removed (tables I-II). Table III shows pre- and post-implant PN-SSEPs findings in patients with 
durable beneficial from SNM. In patients undergone implant removal, values of PN-SSEPs, EAS-EMG and PAR were normal 
apart one case with an increase in bilateral pudendal nerve latency. Figure I shows pre-implant EAS-EMG findings in patients 
having beneficial from SNM. Pre-implant EAS-EMG findings were normal in 90.9% of patient undergone implant removal. Table 
IV summarizes pre- and post-implant R1 and R2 latencies of PAR in patients with effective SNM implant.  
 
Interpretation of results 
The greater effectiveness of SNM has been observed in patients with neurological damage neurophysiologically documented. 
To date there are no definitive data about the exact mechanism of action of SNM although it is conceivable a modulation on the 
somato-sensory afferents as well as a secondary effect on both somatic (pudendal nerve) and autonomic efferent motor 
pathways.  
 
Concluding message 
Our results suggest that the neurophysiologic exploration of the pelvic floor is an important step for the identification of suitable 
candidates for treatment with SNM. Further well-designed trials are needed in order to better define the role of neurophysiology 
in SNM, not just in identifying appropriate candidates for intervention, but also to guide the surgeon in more accurate positioning 
of the electrodes, using intraoperative monitoring, and to change the parameters of stimulation in patients unresponsive to 
treatment. 
 
Table I. Characteristics of patients undergone implant removal  
Patients Age Gender LUTD Time interval from temporary implant to removal (months) 
CA 53 Female  UR 4 
FM 78 Female  UR 3 
BAR 71 Female  UR 32 
MRG 37 Female  UR 26 
MM 66 Female  OAB 2 
DFL 21 Female OAB 19 
FA 68 Female  OAB 1 
CM 48 Female  CPP 1 
OM 53 Female  OAB 3 
BL 50 Male UR 3 
MM 83 Female  UR 2 
 
Table II. Characteristics of patients having durable beneficial from SNM  
Patients Age Gender LUTD Follow-up (months) 
GM 37 Male  OAB 26 
RL 75 Female  OAB 27 
BA 71 Female  OAB 54 
FP 73 Female  OAB 55 
GR 77 Female  OAB 33 
BP 28 Female  CPP 31 
ZL 58 Female  OAB 26 
FG 80 Female  OAB 26 
CA 73 Female  OAB 21 
MA 66 Female OAB 15 
BA 40 Female  UR 21 
 
Table III. Pre- and post-implant PN-SSEPs findings in patients with durable beneficial from SNM (SD*: Standard Deviation) 
Parameter Right side 
(pre-implant) 
mean (SD*) 
Right side 
(post-implant) 
mean (SD*) 
 
P value Left side (pre-
implant) 
mean (SD*) 
Left side   
(post-implant) 
mean (SD*) 
P value 
Latency 38.52 (3.74) 37.11 (4.2) 0.17 37.11 (4.2) 34.92 (29.33) 0.10 
Distal 
amplitude 
3.29 (2.99) 3.95 (0.99) 0.01 2.07 (3.23) 1.79 (0.96) 0.05 
 
Figure I. Pre-implant EAS-EMG findings in patients having beneficial from SNM.  
 
Table IV. Pre- and post-implant R1 and R2 latencies of PAR in patients with effective SNM implant. (NS*: Not Significant) 
Parameter Right side 
(pre-implant) 
mean  
Right side 
(post-implant) 
mean 
 
P 
value 
Left side (pre-
implant) 
mean  
Left side   
(post-implant) 
mean  
P value  
R1 Latency 34.05 39.10 NS* 34.78 38.40 NS* 
2 Latency  60.47 61.25 NS* 61.14 63.84 NS* 
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